Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bortezomib + rituximab in relapsed or refractory indolent non-follicular and mantle cell non-Hodgkin lymphoma
2006-003657-24Phase 2Completed
- Sponsor
- Gimurell
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and rituximab in non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 3 more, sponsored by Gimurell. Primary endpoint: Overall response rate. Started Oct 2006; status: completed.
02
Drugs
bortezomibrituximab
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2006-003657-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003657-24.